The future role of target of rapamycin inhibitors in renal transplantation

Current Opinion in Urology

Volumn 12, Issue 2, 2002, Pages 109-113

  Schwarz, Christoph ^a   Oberbauer, Rainer ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RAPAMYCIN INHIBITOR; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; GLOMERULUS FILTRATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL;

CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS;

EID: 0036176782     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200203000-00005     Document Type: Review

References (24)

1. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation
2. The UNOS Scientific Renal Transplant Registry: 2000
3. Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management
4. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization
5. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle
6. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy
7. Sirolimus (rapamycin), an immunosuppressant that inhibits lymphocyte activation, protects against aortic atherosclerosis in cholesterol-fed apo E-deficient mice
8. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure
9. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial
10. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
11. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
12. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study
13. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
14. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations
15. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
16. Sirolimus does not exhibit the nephrotoxicity associated with cyclosporine administration in renal transplant receipients
17. Sirolimus maintenance therapy results in improved renal function: 12-months results of the tri-continental trial
18. Hyperuricemia exacerbates chronic cyclosporine nephropathy
19. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes
20. Sirolimus-tacrolimus combination immunosuppression
21. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
22. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine
23. RAD in de novo renal transplantation: Comparison of three doses on the incidence and severity of acute rejection